Investigators at Ann & Robert H. Lurie Children's Hospital (Lurie Children's) invite you to consider participating in a research study:

A Phase 1, First-in-Human, Multiple Part, Single Ascending and Multiple Dose Study of JNT-517 in Healthy Participants and in Participants with Phenylketonuria.

Sponsored by: Jnana Therapeutics, Inc. and carried out by Barbara Burton, M.D.

Dear Potential Participant:

The research team at Lurie Children's Hospital is reaching out to let you know about A Phase 1, First-in-Human, Multiple Part, Single Ascending and Multiple Dose study of JNT-517 in Healthy Participants and in Participants with Phenylketonuria. We are currently recruiting adults (ages 18-65) who have PKU for this research study.

The purpose of this study is to learn about the effects (good and/or bad) JNT-517 has on adults and their PKU. More specifically, this study will help us learn if JNT-517 is safe in controlling blood Phe levels in adult. Participants will be assigned to 1 of 2 groups in the study. One group will receive JNT-517 and the other group will not. Participants will be in the study for about 3 months.

If you are interested in learning more, please contact any of the research team members at the phone numbers or emails listed below.

Thank you and we look forward to hearing from you!

Sincerely,

Phillip Luu Clinical Research Coordinator 312.227.6128 pluu@luriechildrens.org

Dejavette Yang Clinical Research Coordinator 312.227.2481 dgyang@luriechildrens.org Carolyn Prokop Clinical Research Coordinator 312.227.6004 ccprokop@luriechildrens.org